Nemes Rush Group’s Tandem Diabetes Care TNDM Stock Holding History

Nemes Rush Group’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8	Closed	-$176	–	1032
2025 Q4	$176	Buy	+8	New	+$144	﹤0.01%	937

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nemes Rush Group's TNDM Position: Q1 2026 in Review

Nemes Rush Group sold out of Tandem Diabetes Care (TNDM) in Q1 2026, closing a stake of 8 shares — an estimated $176 sold.

Nemes Rush Group first reported a position in TNDM in Q4 2025 and held it in 1 quarter. The position peaked at $176 in Q4 2025. 273 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

Nemes Rush Group reported no remaining Tandem Diabetes Care position as of Q1 2026 after selling out during the quarter.
Nemes Rush Group sold 8 Tandem Diabetes Care shares in Q1 2026, an estimated $176.
Nemes Rush Group first reported a position in Tandem Diabetes Care in Q4 2025 and held it in 1 quarter.
Nemes Rush Group's Tandem Diabetes Care position peaked at $176 in Q4 2025.
273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.